Literature DB >> 579516

Heparin elimination in patients with liver cirrhosis.

A N Teien.   

Abstract

Heparin (100 U/kg body-weight) was injected intravenously, and heparin concentration in plasma determined by polybrene titration. Mean heparin half-life was 117.8 min in a group of patients with liver cirrhosis and normal renal function (n = 6) as compared to 74.0 min in the normal group (n = 6). The difference between the two groups is statistically significant (p approximately 0.02). Heparin half-life was correlated to galactose half-life in the patients (r=0.83, p= 0.05). The findings suggest that heparin is metabolized in the liver. There was a significant fall in antithrombin III activities in the normals, but not in the patients. A possible explanation may be that the normal liver removes heparin bound to antithrombin III, and that this function is impaired in liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 579516

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Heparin-like effect resistant to protamine in a child with haemorrhagic shock. Do we need heparinase?

Authors:  Mirco Nacoti; Diego Cantù; Daniele Bonacina; Federico Lussana; Ezio Bonanomi; Marina Marchetti; Anna Falanga
Journal:  Blood Transfus       Date:  2017-06-08       Impact factor: 3.443

Review 2.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

3.  Endogenous Heparin-Like Substances May Cause Coagulopathy in a Patient with Severe Postpartum Hemorrhage.

Authors:  Shichun Wang; Chao Qi; Zhicheng Liu; Ting Xu; Chunyan Yao
Journal:  Transfus Med Hemother       Date:  2019-12-05       Impact factor: 3.747

4.  Plasma concentrations of endogenous heparinoids in portal hypertension.

Authors:  R F McKee; S Hodson; J Dawes; O J Garden; D C Carter
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

Review 5.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of heparin.

Authors:  J W Estes
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 7.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.